查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1715334

細胞治療市場按類型、治療類型、交付模式、應用和最終用戶分類—2025-2030 年全球預測

Cell Therapy Market by Type, Therapy Type, Mode of Administration, Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

細胞治療市場預期到 2024 年將達到 96 億美元，到 2025 年將達到 106.4 億美元，到 2030 年將達到 179.1 億美元，複合年成長率為 10.94%。

主要市場統計數據
基準年2024年 96億美元
預計2025年 106.4億美元
預測年份 2030 179.1億美元
複合年成長率（%） 10.94%

細胞療法已成為現代醫學的突破性工具，並正在穩步改變各種嚴重健康狀況的治療模式。這項全面的調查深入研究了細胞療法的開發、改進和最終應用於臨床實踐的動態環境。生物技術的進步和對細胞機制的深入了解正在加速從傳統治療方法轉向利用活細胞潛力的創新治療方法的轉變。該分析強調了這一演變的意義，並強調了推動市場成長的科學突破和商業性驅動力。讀者將全面了解該領域先驅者面臨的策略促進因素、關鍵促進因素和潛在挑戰。透過深入研究市場複雜性，包括不斷變化的監管格局和突破性的科學見解，本報告為理解細胞療法如何塑造未來的治療方法奠定了堅實的基礎。報告的每個部分都旨在指南決策者和行業專業人士清晰、準確地探索這個複雜但充滿希望的領域。

重新定義細胞治療生態系的轉折點

近年來，細胞治療領域發生了重大變化，創新不斷突破醫學可能性的界限。隨著新的科學見解和技術進步的融合，該行業正在經歷快速變化，重新定義研究、應用和商業化。由於對技術和臨床基礎設施的大量投資，曾經停留在實驗室的開創性治療方法正在走向現實世界的應用。這種轉變體現在精準醫療的整合上，其中治療越來越根據個別患者情況進行客製化。同時，新的細胞工程方法正在提高治療性介入的效率和安全性，為更有針對性和可控的應用鋪平了道路。世界各地的法律規範開始不斷發展，以反映技術創新的快速步伐並確保安全標準能夠跟上新技術。學術界、生技公司和大型製造公司之間的合作正在進一步加速研發舉措。這些轉變共同推動市場進入一個新時代，在這個新時代，既定的協議不斷受到創新方法的挑戰，持續的研究投資對於長期成功至關重要。

細胞治療市場的詳細細分洞察

分析細胞治療市場需要對其複雜的細分有細緻的了解。本研究根據幾個關鍵標準來檢驗這種情況：首先，市場可以分為非幹細胞類型和幹細胞類型。非幹細胞又分為CAR-T細胞、樹突狀細胞、NK細胞等，每種細胞都表現出各自的臨床優勢和治療多功能性。相較之下，幹細胞領域則透過細分的片段進行嚴格探索，包括胚胎幹細胞、造血幹細胞和間質幹細胞，它們提供了多樣化的治療潛力。然後，分析深入研究治療類型，將其分為順勢療法和自體療法。這種區別至關重要，因為每種治療類型不僅在臨床應用上有所不同，而且在製造複雜性和法律規範也有所不同。為了進一步深化分析，市場根據給藥方式進行細分，包括肌肉注射、腫瘤內注射和靜脈注射。與這些方法相關的不同功效和安全性需要清楚了解臨床偏好和後勤挑戰。此外，基於應用的細分揭示了不同疾病狀態下的機會。主要應用領域包括自體免疫疾病、癌症治療、感染疾病、再生醫學等。其中，我們正在對自體免疫疾病的多發性硬化症和類風濕性關節炎、癌症治療中的骨髓惡性腫瘤和固態腫瘤、感染疾病中的細菌感染和病毒感染的區別等子領域進行詳細的研究。最後，按最終用戶細分，突顯了學術和研究機構、診所、商業實驗室和醫院在推動市場需求方面的作用。每個細分市場都受到影響需求和技術創新的獨特因素的影響，有助於更深入地了解市場動態和未來成長軌跡。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 全球癌症、心血管疾病等慢性病的發生率不斷上升
      • 各地區政府支持政策及資金
      • 消費者和醫療保健專業人士的意識不斷提高，凸顯了細胞療法的重要性。
    • 限制因素
      • 細胞療法治療費用高昂，限制了更廣泛的患者群體獲得治療
    • 機會
      • 基因編輯的廣泛應用將改變治療能力
      • 加大研發投入，加強生技公司與學術機構的合作
    • 任務
      • 保持細胞治療的一致性和擴充性的挑戰
  • 市場區隔分析
    • 類型：在某些血癌治療中，非幹細胞的偏好日益增加
    • 最終使用者：高級護理診所中細胞療法的使用增加
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社會
    • 技術的
    • 合法的
    • 環境

第6章 細胞治療市場（按類型）

  • 非幹細胞
    • CAR-T細胞
    • 樹突狀細胞
    • NK細胞
  • 幹細胞
    • 胚胎幹細胞
    • 造血幹細胞
    • 間質幹細胞

第7章 細胞治療市場（依治療類型）

  • 同種異體
  • 自體移植

8. 細胞治療市場（依給藥方式）

  • 肌肉注射
  • 腫瘤內
  • 靜脈

第9章 細胞治療市場：依應用

  • 自體免疫疾病
    • 多發性硬化症
    • 類風濕性關節炎
  • 癌症治療
    • 造血系統惡性腫瘤
    • 固態腫瘤
  • 感染疾病
    • 細菌感染疾病
    • 病毒感染
  • 再生醫學

第 10 章 細胞治療市場（依最終使用者分類）

  • 學術研究所
  • 診所
  • 商業研究所
  • 醫院

第 11 章：美洲細胞治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太細胞治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

13. 歐洲、中東和非洲細胞治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • Anterogen Co., Ltd.
  • Astellas Pharma Inc.
  • Athersys, Inc.
  • BioNTech SE
  • Bristol-Myers Squibb Company
  • Castle Creek Biosciences, Inc.
  • Catalent, Inc.
  • FUJIFILM Holdings Corporation
  • Gilead Sciences, Inc.
  • JCR Pharmaceuticals Co., Ltd.
  • Kolon TissueGene, Inc.
  • Lonza Group Ltd.
  • Medipost Co., Ltd.
  • Mesoblast Ltd.
  • Novartis AG
  • NuVasive, Inc.
  • Pfizer Inc.
  • Sartorius AG
  • Stemedica Cell Technologies, Inc.
  • Stempeutics Research Pvt. Ltd.
  • Takeda Pharmaceutical Company Limited
  • TegoScience
  • Thermo Fisher Scientific, Inc.
  • Vericel Corporation
Product Code: MRR-433AB1DC28D4

The Cell Therapy Market was valued at USD 9.60 billion in 2024 and is projected to grow to USD 10.64 billion in 2025, with a CAGR of 10.94%, reaching USD 17.91 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 9.60 billion
Estimated Year [2025] USD 10.64 billion
Forecast Year [2030] USD 17.91 billion
CAGR (%) 10.94%

Cell therapy has emerged as a groundbreaking avenue in modern medicine, steadily transforming treatment paradigms across a range of critical health conditions. This comprehensive study provides a detailed exploration of the dynamic environment in which cell therapies are developed, refined, and ultimately applied in clinical settings. Advancements in biotechnology and a deeper understanding of cellular mechanisms have accelerated the shift from traditional treatments to innovative therapies that harness the potential of living cells. In this analysis, we underline the importance of this evolution, highlighting both the scientific breakthroughs and the commercial impetus driving market growth. Readers will gain a well-rounded view of the strategic factors, key drivers, and potential challenges facing pioneers in this field. By delving into the market's intricacies, including evolving regulatory landscapes and breakthrough scientific insights, this report lays a robust foundation for understanding how cell therapy is shaping future treatment modalities. The ensuing sections are designed to guide decision-makers and industry experts in navigating this complex yet promising frontier with clarity and authority.

Transformative Shifts Redefining the Cell Therapy Ecosystem

The landscape of cell therapy has undergone a profound transformation over recent years, with innovation pushing the boundaries of what is medically possible. As new scientific insights and technological advancements converge, the industry is experiencing radical changes that redefine research, application, and commercialization. Pioneering therapies that were once confined to laboratories are now moving towards real-world applications, driven by significant investments in technology and clinical infrastructure. This transformation is marked by the integration of precision medicine, where treatments are increasingly customized to individual patient profiles. In parallel, new methods in cell engineering have enhanced the efficiency and safety of therapeutic interventions, paving the way for more targeted and controlled applications. Regulatory frameworks around the world have started to evolve, reflecting the swift pace of innovation and ensuring that safety standards keep up with emerging technologies. Collaborations between academia, biotechnology firms, and large-scale manufacturing entities have further accelerated research and development initiatives. Together, these shifts are propelling the market into a new era where established protocols are continuously challenged by innovative approaches, and where sustained investment in research is critical for long-term success.

Detailed Segmentation Insights in the Cell Therapy Market

Analyzing the cell therapy market requires a nuanced understanding of its complex segmentation. The study examines the landscape based on several pivotal criteria. First, when segmented by type, the market distinguishes between Non-stem Cells and Stem Cells. The Non-stem Cell category is further divided into segments such as CAR-T Cells, Dendritic Cells, and NK Cells, each demonstrating unique clinical advantages and treatment versatility. In contrast, the Stem Cell segment is rigorously studied through its subdivisions, encompassing Embryonic Stem Cells, Hematopoietic Stem Cells, and Mesenchymal Stem Cells, which offer diverse therapeutic potentials. The analysis then delves into therapy types, categorizing offerings as Allogenic or Autologous therapies. This distinction is critical, as each therapy type varies not only in clinical application but also in manufacturing complexity and regulatory oversight. Further deepening the analysis, the market is segmented according to the mode of administration, examining practices such as Intramuscular, Intratumoral, and Intravenous delivery. The varied efficacy and safety profiles associated with these methods require a clear understanding of clinical preferences and logistical challenges. Moreover, the application-based segmentation uncovers opportunities in a diverse range of medical conditions. Key application areas include Autoimmune Disorders, Cancer Treatment, Infectious Diseases, and Regenerative Medicine. Within these, detailed investigations extend to sub-fields like Multiple Sclerosis and Rheumatoid Arthritis for Autoimmune Disorders, Hematologic Malignancies and Solid Tumors for Cancer Treatment, and distinctions between Bacterial Infections and Viral Infections within Infectious Diseases. Lastly, segmentation by end user highlights the role of Academic & Research Institutes, Clinics, Commercial Laboratories, and Hospitals in driving market demand. Each segment, shaped by unique factors influencing demand and innovation, collectively contributes to a deeper understanding of market dynamics and future growth trajectories.

Based on Type, market is studied across Non-stem Cells and Stem Cells. The Non-stem Cells is further studied across CAR-T Cells, Dendritic Cells, and NK Cells. The Stem Cells is further studied across Embryonic Stem Cells, Hematopoietic Stem Cell, and Mesenchymal Stem Cell.

Based on Therapy Type, market is studied across Allogenic and Autologous.

Based on Mode of Administration, market is studied across Intramuscular, Intratumoral, and Intravenous.

Based on Application, market is studied across Autoimmune Disorders, Cancer Treatment, Infectious Diseases, and Regenerative Medicine. The Autoimmune Disorders is further studied across Multiple Sclerosis and Rheumatoid Arthritis. The Cancer Treatment is further studied across Hematologic Malignancies and Solid Tumors. The Infectious Diseases is further studied across Bacterial Infections and Viral Infections.

Based on End User, market is studied across Academic & Research Institutes, Clinics, Commercial Laboratories, and Hospitals.

Global Regional Dynamics Shaping the Cell Therapy Market

A regional perspective reveals that the cell therapy market is not uniformly developed around the world, with distinct geographies contributing in unique ways. In the Americas, robust research ecosystems, strong clinical infrastructure, and supportive regulatory environments have positioned the region as a leader in both innovation and market adoption. Strategic investments along with well-established pharmaceutical and biotechnology sectors have provided the necessary impetus for rapid progress and successful commercialization. In contrast, the combined region of Europe, Middle East & Africa has demonstrated a strategic blend of research excellence and regulatory reform. Innovations in these parts of the world frequently reflect a balance between adherence to strict safety protocols and the agility required to embrace emerging scientific methods. Meanwhile, the Asia-Pacific region has shown remarkable growth, driven primarily by increasing healthcare expenditure and an expanding R&D landscape. Governments in these countries are actively fostering scientific collaborations and ramping up efforts to streamline clinical trials and approvals. Each region contributes distinct strengths such as technological prowess, market scale, or regulatory agility, thereby enriching the overall market architecture. These regional insights provide a holistic understanding of how local conditions can significantly influence global trends, offering a roadmap for companies looking to tailor their strategies according to geographic opportunities.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Strategic Company Perspectives in the Cell Therapy Arena

Examining the competitive environment of the cell therapy market sheds light on numerous companies that have positioned themselves as innovators and key drivers for change. Several industry leaders, such as Anterogen Co., Ltd. and Astellas Pharma Inc., are at the forefront of developing advanced treatments while concurrently investing in robust research pipelines. Pioneering firms like Athersys, Inc. and BioNTech SE have propelled scientific advancements through their innovative approaches to cell-based therapies, emphasizing both efficacy and safety. Not to be overlooked, large multinational entities including Bristol-Myers Squibb Company and Novartis AG have significantly broadened their portfolios to incorporate cutting-edge cell therapeutic products. Their expansive networks facilitate collaboration across research, clinical trials, and regulatory environments. Other notable companies, such as Castle Creek Biosciences, Inc. and Catalent, Inc., contribute through precise manufacturing capabilities that enhance product scalability. Enterprises like FUJIFILM Holdings Corporation, Gilead Sciences, Inc., and JCR Pharmaceuticals Co., Ltd. continue to push the envelope with their investments in novel biological constructs. Furthermore, innovative players including Kolon TissueGene, Inc., Lonza Group Ltd., and Medipost Co., Ltd. are critical for introducing next-generation technologies that set new benchmarks in treatment efficacy. In addition, firms such as Mesoblast Ltd. and NuVasive, Inc. are expanding their research horizons and forging strategic partnerships that enable cross-sector synergy. With Pfizer Inc., Sartorius AG, Stemedica Cell Technologies, Inc., and Stempeutics Research Pvt. Ltd. collectively driving technological advancements, the market is witnessing accelerated progress alongside increased investment in state-of-the-art research facilities. Finally, Takeda Pharmaceutical Company Limited, TegoScience, Thermo Fisher Scientific, Inc., and Vericel Corporation continue to build on this momentum, strengthening the infrastructure that underpins market growth. Together, these companies offer varied strategic narratives that collectively enrich insights into the evolving trends and competitive dynamics of the cell therapy market.

The report delves into recent significant developments in the Cell Therapy Market, highlighting leading vendors and their innovative profiles. These include Anterogen Co., Ltd., Astellas Pharma Inc., Athersys, Inc., BioNTech SE, Bristol-Myers Squibb Company, Castle Creek Biosciences, Inc., Catalent, Inc., FUJIFILM Holdings Corporation, Gilead Sciences, Inc., JCR Pharmaceuticals Co., Ltd., Kolon TissueGene, Inc., Lonza Group Ltd., Medipost Co., Ltd., Mesoblast Ltd., Novartis AG, NuVasive, Inc., Pfizer Inc., Sartorius AG, Stemedica Cell Technologies, Inc., Stempeutics Research Pvt. Ltd., Takeda Pharmaceutical Company Limited, TegoScience, Thermo Fisher Scientific, Inc., and Vericel Corporation. Actionable Strategic Recommendations for Industry Leaders

Industry leaders are encouraged to adopt a multi-pronged strategy to navigate the challenges and opportunities in cell therapy. It is essential to invest heavily in research and development to adopt novel therapeutic approaches and improve clinical outcomes. Leaders should consider forming strategic alliances with academic institutions and specialized biotechnology firms to gain access to pioneering research and leverage emerging technologies. Embracing flexible regulatory strategies and staying informed on global policy updates can ensure readiness to adapt to sudden market shifts. Furthermore, optimizing manufacturing processes and expanding scalable operations will be critical in meeting increasing market demand. Prioritizing patient-centric innovation and streamlining clinical trial protocols can enhance both efficacy and safety, ensuring competitive differentiation in an increasingly crowded field. By focusing on these key areas, stakeholders can enhance their market positioning and secure long-term success in a rapidly evolving sector.

Conclusion and Future Outlook of the Cell Therapy Market

The analysis presents a vivid picture of a market in flux-where transformative scientific innovations, robust regional strategies, and a competitive array of companies converge to shape the future of cell therapy. Throughout this study, it has become evident that technological and regulatory advancements are recalibrating traditional clinical paradigms and offering renewed hope for addressing complex health conditions. The cumulative insights gathered provide a comprehensive overview that not only highlights current opportunities but also outlines the steps necessary for future growth. In summary, while challenges persist, the strategic convergence of investment, innovation, and collaboration appears poised to propel the cell therapy market to new heights. Decision-makers and industry specialists are now better equipped to harness these insights, guiding the sector towards more efficient, streamlined, and impactful therapeutic interventions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of chronic diseases such as cancer and cardiovascular diseases worldwide
      • 5.1.1.2. Supportive government policies and funding in various regions
      • 5.1.1.3. Rising awareness among consumers and healthcare professionals underscores the importance of cell therapy
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of cell therapy treatment limiting accessibility for broader patient populations
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing utilization of gene-editing technologies transform cell therapy treatment capabilities
      • 5.1.3.2. Rising investments in R&D and collaborations between biotech companies and academic institutions
    • 5.1.4. Challenges
      • 5.1.4.1. Issues related to maintaining consistency and scalability in cell therapies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Rising preference for non-stem cells to treat certain blood cancers
    • 5.2.2. End User: Rising use of cell therapy in clinics to deliver advanced treatments
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cell Therapy Market, by Type

  • 6.1. Introduction
  • 6.2. Non-stem Cells
    • 6.2.1. CAR-T Cells
    • 6.2.2. Dendritic Cells
    • 6.2.3. NK Cells
  • 6.3. Stem Cells
    • 6.3.1. Embryonic Stem Cells
    • 6.3.2. Hematopoietic Stem Cell
    • 6.3.3. Mesenchymal Stem Cell

7. Cell Therapy Market, by Therapy Type

  • 7.1. Introduction
  • 7.2. Allogenic
  • 7.3. Autologous

8. Cell Therapy Market, by Mode of Administration

  • 8.1. Introduction
  • 8.2. Intramuscular
  • 8.3. Intratumoral
  • 8.4. Intravenous

9. Cell Therapy Market, by Application

  • 9.1. Introduction
  • 9.2. Autoimmune Disorders
    • 9.2.1. Multiple Sclerosis
    • 9.2.2. Rheumatoid Arthritis
  • 9.3. Cancer Treatment
    • 9.3.1. Hematologic Malignancies
    • 9.3.2. Solid Tumors
  • 9.4. Infectious Diseases
    • 9.4.1. Bacterial Infections
    • 9.4.2. Viral Infections
  • 9.5. Regenerative Medicine

10. Cell Therapy Market, by End User

  • 10.1. Introduction
  • 10.2. Academic & Research Institutes
  • 10.3. Clinics
  • 10.4. Commercial Laboratories
  • 10.5. Hospitals

11. Americas Cell Therapy Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Cell Therapy Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Cell Therapy Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Pluri launches new cell therapy CDMO division
    • 14.3.2. Max Healthcare launches CAR-T cell therapy
    • 14.3.3. Bayer opens cell therapy manufacturing facility to advance regenerative medicines on a global scale
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Anterogen Co., Ltd.
  • 2. Astellas Pharma Inc.
  • 3. Athersys, Inc.
  • 4. BioNTech SE
  • 5. Bristol-Myers Squibb Company
  • 6. Castle Creek Biosciences, Inc.
  • 7. Catalent, Inc.
  • 8. FUJIFILM Holdings Corporation
  • 9. Gilead Sciences, Inc.
  • 10. JCR Pharmaceuticals Co., Ltd.
  • 11. Kolon TissueGene, Inc.
  • 12. Lonza Group Ltd.
  • 13. Medipost Co., Ltd.
  • 14. Mesoblast Ltd.
  • 15. Novartis AG
  • 16. NuVasive, Inc.
  • 17. Pfizer Inc.
  • 18. Sartorius AG
  • 19. Stemedica Cell Technologies, Inc.
  • 20. Stempeutics Research Pvt. Ltd.
  • 21. Takeda Pharmaceutical Company Limited
  • 22. TegoScience
  • 23. Thermo Fisher Scientific, Inc.
  • 24. Vericel Corporation

LIST OF FIGURES

  • FIGURE 1. CELL THERAPY MARKET MULTI-CURRENCY
  • FIGURE 2. CELL THERAPY MARKET MULTI-LANGUAGE
  • FIGURE 3. CELL THERAPY MARKET RESEARCH PROCESS
  • FIGURE 4. CELL THERAPY MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL CELL THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CELL THERAPY MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL CELL THERAPY MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL CELL THERAPY MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL CELL THERAPY MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL CELL THERAPY MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL CELL THERAPY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 19. AMERICAS CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES CELL THERAPY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 21. UNITED STATES CELL THERAPY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 27. CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CELL THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CELL THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CELL THERAPY MARKET DYNAMICS
  • TABLE 7. GLOBAL CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CELL THERAPY MARKET SIZE, BY CAR-T CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CELL THERAPY MARKET SIZE, BY DENDRITIC CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CELL THERAPY MARKET SIZE, BY NK CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CELL THERAPY MARKET SIZE, BY STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CELL THERAPY MARKET SIZE, BY EMBRYONIC STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CELL THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CELL THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CELL THERAPY MARKET SIZE, BY ALLOGENIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CELL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CELL THERAPY MARKET SIZE, BY INTRATUMORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CELL THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CELL THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CELL THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL CELL THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL CELL THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL CELL THERAPY MARKET SIZE, BY REGENERATIVE MEDICINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL CELL THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL CELL THERAPY MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL CELL THERAPY MARKET SIZE, BY COMMERCIAL LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL CELL THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. BRAZIL CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 72. BRAZIL CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 73. BRAZIL CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 74. BRAZIL CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. CANADA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. CANADA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. CANADA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. CANADA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 82. CANADA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 83. CANADA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 84. CANADA CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. MEXICO CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. MEXICO CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 87. MEXICO CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 88. MEXICO CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. MEXICO CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. MEXICO CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. MEXICO CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 92. MEXICO CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. MEXICO CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 94. MEXICO CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED STATES CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED STATES CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED STATES CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED STATES CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED STATES CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED STATES CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED STATES CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED STATES CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED STATES CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED STATES CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED STATES CELL THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 117. AUSTRALIA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. AUSTRALIA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 119. AUSTRALIA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 120. AUSTRALIA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. AUSTRALIA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. AUSTRALIA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. AUSTRALIA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 124. AUSTRALIA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 126. AUSTRALIA CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. CHINA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. CHINA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 129. CHINA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 130. CHINA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. CHINA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. CHINA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. CHINA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 134. CHINA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 135. CHINA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 136. CHINA CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. INDIA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. INDIA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 139. INDIA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 140. INDIA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. INDIA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. INDIA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. INDIA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 144. INDIA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 145. INDIA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 146. INDIA CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 147. INDONESIA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. INDONESIA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 149. INDONESIA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 150. INDONESIA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. INDONESIA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 152. INDONESIA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. INDONESIA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 154. INDONESIA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 155. INDONESIA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 156. INDONESIA CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 157. JAPAN CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. JAPAN CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 159. JAPAN CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 160. JAPAN CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. JAPAN CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 162. JAPAN CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. JAPAN CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 164. JAPAN CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 165. JAPAN CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 166. JAPAN CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 167. MALAYSIA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. MALAYSIA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 169. MALAYSIA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 170. MALAYSIA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. MALAYSIA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. MALAYSIA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. MALAYSIA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 174. MALAYSIA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 175. MALAYSIA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 176. MALAYSIA CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 177. PHILIPPINES CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. PHILIPPINES CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 179. PHILIPPINES CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 180. PHILIPPINES CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. PHILIPPINES CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 182. PHILIPPINES CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 183. PHILIPPINES CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 184. PHILIPPINES CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 185. PHILIPPINES CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 186. PHILIPPINES CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 187. SINGAPORE CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. SINGAPORE CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 189. SINGAPORE CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 190. SINGAPORE CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. SINGAPORE CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 192. SINGAPORE CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. SINGAPORE CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 194. SINGAPORE CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 195. SINGAPORE CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 196. SINGAPORE CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 197. SOUTH KOREA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. SOUTH KOREA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH KOREA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH KOREA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH KOREA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH KOREA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH KOREA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH KOREA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH KOREA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH KOREA CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 207. TAIWAN CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. TAIWAN CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 209. TAIWAN CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 210. TAIWAN CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. TAIWAN CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 212. TAIWAN CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 213. TAIWAN CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 214. TAIWAN CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 215. TAIWAN CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 216. TAIWAN CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 217. THAILAND CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. THAILAND CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 219. THAILAND CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 220. THAILAND CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. THAILAND CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 222. THAILAND CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 223. THAILAND CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 224. THAILAND CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 225. THAILAND CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 226. THAILAND CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 227. VIETNAM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. VIETNAM CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 229. VIETNAM CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 230. VIETNAM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. VIETNAM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 232. VIETNAM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 233. VIETNAM CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 234. VIETNAM CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 235. VIETNAM CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 236. VIETNAM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 248. DENMARK CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. DENMARK CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 250. DENMARK CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 251. DENMARK CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 252. DENMARK CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 253. DENMARK CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 254. DENMARK CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 255. DENMARK CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 256. DENMARK CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 257. DENMARK CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 258. EGYPT CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 259. EGYPT CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 260. EGYPT CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 261. EGYPT CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 262. EGYPT CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 263. EGYPT CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 264. EGYPT CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 265. EGYPT CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 266. EGYPT CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 267. EGYPT CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 268. FINLAND CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. FINLAND CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 270. FINLAND CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 271. FINLAND CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 272. FINLAND CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 273. FINLAND CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 274. FINLAND CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 275. FINLAND CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 276. FINLAND CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 277. FINLAND CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 278. FRANCE CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 279. FRANCE CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 280. FRANCE CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 281. FRANCE CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 282. FRANCE CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 283. FRANCE CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 284. FRANCE CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 285. FRANCE CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 286. FRANCE CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 287. FRANCE CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 288. GERMANY CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 289. GERMANY CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 290. GERMANY CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 291. GERMANY CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 292. GERMANY CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 293. GERMANY CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 294. GERMANY CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 295. GERMANY CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 296. GERMANY CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 297. GERMANY CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 298. ISRAEL CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 299. ISRAEL CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 300. ISRAEL CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 301. ISRAEL CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 302. ISRAEL CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 303. ISRAEL CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 304. ISRAEL CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 305. ISRAEL CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 306. ISRAEL CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 307. ISRAEL CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 308. ITALY CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 309. ITALY CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 310. ITALY CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 311. ITALY CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 312. ITALY CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 313. ITALY CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 314. ITALY CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 315. ITALY CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 316. ITALY CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 317. ITALY CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 318. NETHERLANDS CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 319. NETHERLANDS CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 320. NETHERLANDS CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 321. NETHERLANDS CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 322. NETHERLANDS CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 323. NETHERLANDS CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 324. NETHERLANDS CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 325. NETHERLANDS CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 326. NETHERLANDS CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 327. NETHERLANDS CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 328. NIGERIA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 329. NIGERIA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 330. NIGERIA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 331. NIGERIA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 332. NIGERIA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 333. NIGERIA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 334. NIGERIA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 335. NIGERIA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 336. NIGERIA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 337. NIGERIA CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 338. NORWAY CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 339. NORWAY CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 340. NORWAY CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 341. NORWAY CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 342. NORWAY CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 343. NORWAY CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 344. NORWAY CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 345. NORWAY CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 346. NORWAY CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 347. NORWAY CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 348. POLAND CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 349. POLAND CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 350. POLAND CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 351. POLAND CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 352. POLAND CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 353. POLAND CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 354. POLAND CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 355. POLAND CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 356. POLAND CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 357. POLAND CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 358. QATAR CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 359. QATAR CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 360. QATAR CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 361. QATAR CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 362. QATAR CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 363. QATAR CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 364. QATAR CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 365. QATAR CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 366. QATAR CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 367. QATAR CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 368. RUSSIA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 369. RUSSIA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 370. RUSSIA CELL THER